← Eichor
Condition: Clear Cell Metastatic Renal Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Clear Cell Metastatic Renal Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell
Phase 1/Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT06866262A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
EARLY_Phase 1 · 3 location(s) · Chinese PLA General Hospital · NCT07645690A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
Phase 2 · 2 location(s) · Stephanie Berg · NCT07123090Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Phase 2 · 6 location(s) · Vanderbilt-Ingram Cancer Center · NCT05361720Radiopharmaceutical Treatment of Advanced Kidney Cancer
Phase 2 · 2 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06783348Dual-energy SPEctral CT to Evaluate Response to First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer
Phase N/A · 2 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06863857Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
EARLY_Phase 1 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05188118The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial
NA · 3 location(s) · Yonsei University · NCT05753839A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1/Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06835972Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Phase 2 · 1 location(s) · Kelly Fitzgerald, MD · NCT07043608CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
Phase 2 · 5 location(s) · Jinling Hospital, China · NCT07615348Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Car
Phase 3 · 134 location(s) · Arcus Biosciences, Inc. · NCT07011719Combination of Toripalimab and JS004 Therapy for ccRCC
Phase 2 · 1 location(s) · Fudan University · NCT06690697Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Phase 2 · 1 location(s) · Fox Chase Cancer Center · NCT05263050Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C
Phase 2 · 4 location(s) · Karie Runcie · NCT06863311An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
NA · 1 location(s) · University of Texas Southwestern Medical Center · NCT04623502GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
Phase 1 · 1 location(s) · NYU Langone Health · NCT07179770Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Phase 1/Phase 2 · 5 location(s) · Oncorena AB · NCT05287945A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for A
Phase 1/Phase 2 · 24 location(s) · Regeneron Pharmaceuticals · NCT03972657Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met
Phase 1 · 2 location(s) · City of Hope Medical Center · NCT07128680Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Phase N/A · 1 location(s) · Jinling Hospital, China · NCT06676527
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.